Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeRADIATION ONCOLOGYNeolys Diagnostics to Present Strong Supportive Data at ESTRO of Its Predictive...

Neolys Diagnostics to Present Strong Supportive Data at ESTRO of Its Predictive Test for Patients before Radiotherapy

The company, Neolys Diagnostics develops efficient solutions to help decision-making for clinicians and adapt treatment to individual radiosensitivity of each patient.

During the ESTRO (European Society for Radiotherapy and Oncology) Congress in Vienna, Dr Guillaume Vogin (Institut de Cancérologie de Lorraine, Nancy, France) presented the results of Neolys Diagnostics predictive test for patients at risk of toxicity during radiotherapy.

G. Vogin, L. Bodgi, A. Canet, S. Pereira, N. Foray

In this study, Immunofluorescence experiments were performed on the COPERNIC collection of 100 skin fibroblasts from patients irradiated at 2 Gy. Biomarkers of DNA double strand breaks (DSB) recognition and repair were assessed from 10 minutes to 24 hours after irradiation, including the relocalization of phosphorylated ATM Protein (pATM) as nuclear foci. These biological results were plotted against the CTCAE grades. A ROC curve analysis was then performed on patients after they were merged in two groups: radioresistant (grade <2) and radiosensitive (grade ≥2).

Results showed that a delay in the nucleoshuttling of the ATM protein, which is involved in the recognition of the DNA Double Strand Breaks was a common feature to patients with overreaction (OR). When taken as a binary predictive assay with the optimal cut off value, ATM showed promising predictive performances, with an AUC of 0.97, a PPV of 99%, a specificity of 92% and a sensitivity of 100%.

Julien GILLET-DAUBIN, CEO of Neolys Diagnostics stated: ‘Our collaboration with Dr Vogin is of crucial importance for Neolys, and the quality of our results are a very positive signal towards patients and physicians. With four prospective confirmation studies in different indications actively recruiting, we expect to bring innovative and efficient solutions to the market in the next coming years’.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy